Naveen Karkada

826 total citations
25 papers, 329 citations indexed

About

Naveen Karkada is a scholar working on Cardiology and Cardiovascular Medicine, Epidemiology and Infectious Diseases. According to data from OpenAlex, Naveen Karkada has authored 25 papers receiving a total of 329 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Cardiology and Cardiovascular Medicine, 12 papers in Epidemiology and 11 papers in Infectious Diseases. Recurrent topics in Naveen Karkada's work include Viral Infections and Immunology Research (12 papers), Viral gastroenteritis research and epidemiology (10 papers) and Hepatitis B Virus Studies (9 papers). Naveen Karkada is often cited by papers focused on Viral Infections and Immunology Research (12 papers), Viral gastroenteritis research and epidemiology (10 papers) and Hepatitis B Virus Studies (9 papers). Naveen Karkada collaborates with scholars based in Belgium, India and United States. Naveen Karkada's co-authors include Htay Htay Han, Nigel A. Cunliffe, Shabir A. Madhi, A. Duncan Steele, Frank Struyf, Nicolas Folschweiller, Li‐Min Huang, Gary Dubin, Lan Lin and Martin Ryser and has published in prestigious journals such as JNCI Journal of the National Cancer Institute, The Journal of Infectious Diseases and The Pediatric Infectious Disease Journal.

In The Last Decade

Naveen Karkada

25 papers receiving 319 citations

Peers

Countries citing papers authored by Naveen Karkada

Since Specialization

Citations

This map shows the geographic impact of Naveen Karkada's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Naveen Karkada with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Naveen Karkada more than expected).

Fields of papers citing papers by Naveen Karkada

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Naveen Karkada. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Naveen Karkada. The network helps show where Naveen Karkada may publish in the future.

Co-authorship network of co-authors of Naveen Karkada

This figure shows the co-authorship network connecting the top 25 collaborators of Naveen Karkada. A scholar is included among the top collaborators of Naveen Karkada based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Naveen Karkada. Naveen Karkada is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Dynamic borrowing of historical controls adjusting for covariates in vaccine efficacy clinical trials 2024 ·Pharmaceutical Statistics ·Andrea Callegaro, (unknown), Naveen Karkada, Toufik Zahaf	1
2	Vaccine clinical trials with dynamic borrowing of historical controls: Two retrospective studies 2023 ·Pharmaceutical Statistics ·Andrea Callegaro, Naveen Karkada, Emmanuel Aris, Toufik Zahaf	3
3	Inference under covariate-adaptive randomization: A simulation study 2021 ·Statistical Methods in Medical Research ·Andrea Callegaro, (unknown), Naveen Karkada	6
4	Long-Term Persistence of Antibody Response with Two Doses of Inactivated Hepatitis A Vaccine in Children 2020 ·Infectious Diseases and Therapy ·Ashish Agrawal, (unknown), (unknown), Martin O. C. Ota, Selim Badur, Naveen Karkada, Monjori Mitra	3
5	Efficacy of the AS04-adjuvanted HPV-16/18 vaccine in young Chinese women with oncogenic HPV infection at baseline: post-hoc analysis of a randomized controlled trial 2020 ·Human Vaccines & Immunotherapeutics ·Shangying Hu, Xiaoqian Xu, Fengcai Zhu, Ying Hong, Yuemei Hu, Xun Zhang, Qinjing Pan, Wen‐Hua Zhang, Chengfu Zhang, Xiaoping Yang, (unknown), Jiahong Zhu, (unknown), Feng Chen, Shuang Zhao, Naveen Karkada, Haïwen Tang, Dan Bi, Frank Struyf, Fanghui Zhao	11
6	Post-hoc analysis from phase III trials of human papillomavirus vaccines: considerations on impact on non-vaccine types 2019 ·Expert Review of Vaccines ·Martin Ryser, (unknown), Naveen Karkada, Attila Mihalyi, Rino Rappuoli, Robbert van der Most	17
7	A ten-year study of immunogenicity and safety of the AS04-HPV-16/18 vaccine in adolescent girls aged 10-14 years 2019 ·Human Vaccines & Immunotherapeutics ·Tino F. Schwarz, Li‐Min Huang, Alejandra Valencia, (unknown), Cheng‐Hsun Chiu, Annabelle Decreux, Sylviane Poncelet, Naveen Karkada, Nicolas Folschweiller, Lan Lin, Gary Dubin, Frank Struyf	45
8	Efficacy of the AS04-Adjuvanted HPV16/18 Vaccine: Pooled Analysis of the Costa Rica Vaccine and PATRICIA Randomized Controlled Trials 2019 ·JNCI Journal of the National Cancer Institute ·Joseph E. Tota, Frank Struyf, Joshua N. Sampson, Paula González, Martin Ryser, Rolando Herrero, John Schussler, Naveen Karkada, Ana Cecilia Rodríguez, Nicolas Folschweiller, Carolina Porras, Mark Schiffman, John T. Schiller, Wim Quint, Aimée R. Kreimer, Cosette M. Wheeler, Allan Hildesheim, (unknown)	23
9	Long-term Immunogenicity and Safety of the AS04-adjuvanted Human Papillomavirus–16/18 Vaccine in Four- to Six-year-old Girls 2019 ·The Pediatric Infectious Disease Journal ·Lan Lin, (unknown), (unknown), (unknown), (unknown), (unknown), Naveen Karkada, (unknown), L. Mazzotti, Dorota Borys, Frank Struyf	10
10	Immunogenicity and safety of a combined DTPa-IPV/Hib vaccine administered as a three-dose primary vaccination course in healthy Korean infants: phase III, randomized study 2018 ·Human Vaccines & Immunotherapeutics ·Ki Hwan Kim, Chun Soo Kim, Hwang Min Kim, (unknown), (unknown), (unknown), Dong Ho Kim, Pyoung‐Han Hwang, Ji Whan Han, (unknown), Joon Hyung Kim, Naveen Karkada, Narcisa Mesaros, (unknown), Jong‐Hyun Kim	3
11	Benefit Versus Risk Assessment of Rotavirus Vaccination in France: A Simulation and Modeling Analysis 2018 ·BioDrugs ·Edouard Ledent, (unknown), (unknown), (unknown), Naveen Karkada, Nicolas Praet, Gaëlle Nachbaur	7
12	Post-marketing safety surveillance conducted in Korea (2008–2013) following the introduction of the rotavirus vaccine, RIX4414 (Rotarix™) 2016 ·Human Vaccines & Immunotherapeutics ·Son Moon Shin, Chun Soo Kim, Naveen Karkada, Aixue Liu, (unknown), Htay Htay Han	3
13	Serologic response to porcine circovirus type 1 (PCV1) in infants vaccinated with the human rotavirus vaccine, Rotarix™: A retrospective laboratory analysis 2016 ·Human Vaccines & Immunotherapeutics ·Htay Htay Han, Naveen Karkada, (unknown), Gary Dubin	4
14	Immunogenicity and reactogenicity of the human rotavirus vaccine, RIX4414 oral suspension, when co-administered with routine childhood vaccines in Chinese infants 2015 ·Human Vaccines & Immunotherapeutics ·Rongcheng Li, Teng Huang, Yanping Li, (unknown), (unknown), (unknown), (unknown), Yi Nong, Zhaojun Mo, Xueyan Liao, (unknown), Haïwen Tang, (unknown), Naveen Karkada, Htay Htay Han	13
15	Safety and reactogenicity of the combined diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzaetype b (DTPa-IPV/Hib) vaccine in healthy Vietnamese toddlers: An open-label, phase III study 2015 ·Human Vaccines & Immunotherapeutics ·Đặng Đức Anh, Olivier Van Der Meeren, Naveen Karkada, Deepak Assudani, (unknown), Htay Htay Han	8
16	Reactogenicity and safety of the human rotavirus vaccine,Rotarix™ in The Philippines, Sri Lanka, and India: A post-marketing surveillance study 2014 ·Human Vaccines & Immunotherapeutics ·Lulu Bravo, (unknown), Aixue Liu, Jaydeep Choudhury, (unknown), (unknown), (unknown), Pallab Chatterjee, Pankaj Garg, (unknown), (unknown), (unknown), Sundaram Balasubramanian, Naveen Karkada, Htay Htay Han	8
17	Human rotavirus vaccine (RIX4414) efficacy in the first two years of life 2013 ·Human Vaccines & Immunotherapeutics ·Rongcheng Li, Teng Huang, Yanping Li, Dong Luo, (unknown), (unknown), (unknown), Yi Nong, Zhaojun Mo, Xueyan Liao, (unknown), Haïwen Tang, (unknown), Naveen Karkada, Htay Htay Han	38
18	The human rotavirus vaccine Rotarix™ in infants 2013 ·Human Vaccines & Immunotherapeutics ·(unknown), (unknown), Naveen Karkada, Htay Htay Han	14
19	Reactogenicity and safety of a liquid human rotavirus vaccine (RIX4414) in healthy adults, children and infants in China 2013 ·Human Vaccines & Immunotherapeutics ·Rongcheng Li, Yanping Li, Zhaojun Mo, Dong Luo, Teng Huang, (unknown), (unknown), (unknown), Aixue Liu, (unknown), Xueyan Liao, Naveen Karkada, Htay Htay Han	8
20	Association of serum anti-rotavirus immunoglobulin A antibody seropositivity and protection against severe rotavirus gastroenteritis 2013 ·Human Vaccines & Immunotherapeutics ·Brigitte Cheuvart, Kathleen M. Neuzil, A. Duncan Steele, Nigel A. Cunliffe, Shabir A. Madhi, Naveen Karkada, Htay Htay Han, (unknown)	43

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact